688131 皓元医药
已收盘 09-08 15:00:01
资讯
新帖
简况
股市必读：皓元医药新发布《上海皓元医药股份有限公司关于实施2026年半年度权益分派时“皓元转债”停止转股的提示性公告》
证券之星 · 00:43
股市必读：皓元医药新发布《上海皓元医药股份有限公司关于实施2026年半年度权益分派时“皓元转债”停止转股的提示性公告》
9月8日皓元医药涨6.31%，科创创新药ETF国泰基金重仓该股
证券之星 · 09-08 16:39
9月8日皓元医药涨6.31%，科创创新药ETF国泰基金重仓该股
皓元医药涨6.31%，开源证券一周前给出“买入”评级
证券之星 · 09-08 16:38
皓元医药涨6.31%，开源证券一周前给出“买入”评级
每周股票复盘：皓元医药（688131）皓元转债进入回售期
证券之星 · 09-06
每周股票复盘：皓元医药（688131）皓元转债进入回售期
股市必读：皓元医药新发布《国联民生证券承销保荐有限公司关于上海皓元医药股份有限公司2026年半年度持续督导跟踪报告》
证券之星 · 09-04
股市必读：皓元医药新发布《国联民生证券承销保荐有限公司关于上海皓元医药股份有限公司2026年半年度持续督导跟踪报告》
股市必读：皓元医药新发布《上海皓元医药股份有限公司关于“皓元转债”可选择回售的第二次提示性公告》
证券之星 · 09-02
股市必读：皓元医药新发布《上海皓元医药股份有限公司关于“皓元转债”可选择回售的第二次提示性公告》
每周股票复盘：皓元医药（688131）Q2收入增30.43%
证券之星 · 08-30
每周股票复盘：皓元医药（688131）Q2收入增30.43%
皓元医药（688131）2026年中报简析：营收净利润同比双双增长，应收账款上升
证券之星 · 08-28
皓元医药（688131）2026年中报简析：营收净利润同比双双增长，应收账款上升
股市必读：皓元医药新发布《上海皓元医药股份有限公司关于2026年半年度利润分配方案的公告》
证券之星 · 08-27
股市必读：皓元医药新发布《上海皓元医药股份有限公司关于2026年半年度利润分配方案的公告》
图解皓元医药中报：第二季度单季净利润同比增长15.64%
证券之星 · 08-27
图解皓元医药中报：第二季度单季净利润同比增长15.64%
8月25日皓元医药涨6.94%，科创创新药ETF国泰基金重仓该股
证券之星 · 08-25
8月25日皓元医药涨6.94%，科创创新药ETF国泰基金重仓该股
皓元医药（688131）披露关于可转债募投项目暂缓实施及募集资金用途变更的议案获通过，8月24日股价下跌5.88%
证券之星 · 08-24
皓元医药（688131）披露关于可转债募投项目暂缓实施及募集资金用途变更的议案获通过，8月24日股价下跌5.88%
8月24日皓元医药跌5.88%，科创创新药ETF国泰基金重仓该股
证券之星 · 08-24
8月24日皓元医药跌5.88%，科创创新药ETF国泰基金重仓该股
皓元医药：ADC同一厂区一体化模式旨在将抗体原液、高活性载荷、生物偶联及制剂灌装等核心环节集中在同一物理空间内
证券之星 · 08-18
皓元医药：ADC同一厂区一体化模式旨在将抗体原液、高活性载荷、生物偶联及制剂灌装等核心环节集中在同一物理空间内
皓元医药可转债2亿募资项目中途转向 为国联民生项目
中金财经 · 08-18
皓元医药可转债2亿募资项目中途转向 为国联民生项目
每周股票复盘：皓元医药（688131）ADC基地获FDA审计通过
证券之星 · 08-16
每周股票复盘：皓元医药（688131）ADC基地获FDA审计通过
皓元医药（688131）披露募集资金用途调整公告，8月14日股价上涨1.12%
证券之星 · 08-14
皓元医药（688131）披露募集资金用途调整公告，8月14日股价上涨1.12%
8月13日皓元医药涨5.18%，科创创新药ETF国泰基金重仓该股
证券之星 · 08-13
8月13日皓元医药涨5.18%，科创创新药ETF国泰基金重仓该股
CXO强者恒强！药明康德AH股齐升，皓元医药涨超8%！华宝基金医疗ETF（512170）涨超2%冲击五连阳
新浪基金 · 08-13
CXO强者恒强！药明康德AH股齐升，皓元医药涨超8%！华宝基金医疗ETF（512170）涨超2%冲击五连阳
皓元医药(688131.SH)子公司药源启东通过美国FDA审计
智通财经 · 08-12
皓元医药(688131.SH)子公司药源启东通过美国FDA审计
加载更多
公司概况
公司名称：
上海皓元医药股份有限公司
所属行业：
研究和试验发展
上市日期：
2021-06-08
主营业务：
上海皓元医药股份有限公司的主营业务是药物发现领域的生命科学试剂的研发，原料药、中间体、起始物料及制剂的药物研发，工艺优化及商业化生产。公司的主要产品是生命科学试剂业务、原料药和中间体、制剂业务。
发行价格：
64.99
{"stockData":{"symbol":"688131","market":"SH","secType":"STK","nameCN":"皓元医药","latestPrice":94.67,"timestamp":1788850801000,"preClose":89.05,"halted":0,"volume":6058755,"delay":0,"changeRate":0.0631,"floatShares":213000000,"shares":213000000,"eps":1.2158,"marketStatus":"已收盘","change":5.62,"latestTime":"09-08 15:00:01","open":89.08,"high":96.4,"low":88.51,"amount":563000000,"amplitude":0.0886,"askPrice":94.68,"askSize":2,"bidPrice":94.67,"bidSize":5,"shortable":0,"etf":0,"ttmEps":1.2158,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788917400000},"marketStatusCode":5,"adr":0,"adjPreClose":89.05,"symbolType":"stock_kcb","openAndCloseTimeList":[[1788831000000,1788838200000],[1788843600000,1788850800000]],"highLimit":97.96,"lowLimit":80.15,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":213234092,"isCdr":false,"pbRate":6.27,"roa":"--","peRate":77.866425,"roe":"5.3%","epsLYR":1.13,"committee":0.190476,"marketValue":20187000000,"turnoverRate":0.0284,"status":0,"afterMarket":{"amount":18934,"volume":200,"close":94.67,"buyVolume":1633,"sellVolume":0,"time":1788852837746,"indexStatus":"已收盘 09-08 15:30:00","preClose":89.05},"floatMarketCap":20187000000},"requestUrl":"/m/hq/s/688131","defaultTab":"news","newsList":[{"id":"2666374514","title":"股市必读：皓元医药新发布《上海皓元医药股份有限公司关于实施2026年半年度权益分派时“皓元转债”停止转股的提示性公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2666374514","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666374514?lang=zh_cn&edition=full","pubTime":"2026-09-09 00:43","pubTimestamp":1788885795,"startTime":"0","endTime":"0","summary":"公司公告汇总上海皓元医药股份有限公司关于实施2026年半年度权益分派时“皓元转债”停止转股的提示性公告上海皓元医药股份有限公司因实施2026年半年度权益分派，自2026年9月11日至权益分派股权登记日期间，“皓元转债”将停止转股。公司将于2026年9月14日披露权益分派实施公告及转股价格调整公告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090900001962.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688131","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665175325","title":"9月8日皓元医药涨6.31%，科创创新药ETF国泰基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2665175325","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665175325?lang=zh_cn&edition=full","pubTime":"2026-09-08 16:39","pubTimestamp":1788856748,"startTime":"0","endTime":"0","summary":"证券之星消息，9月8日皓元医药涨6.31%，收盘报94.67元，换手率2.84%，成交量6.06万手，成交额5.63亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共28家，其中持有数量最多的公募基金为国泰基金的科创创新药ETF国泰。科创创新药ETF国泰目前规模为21.97亿元，最新净值0.8831，较上一交易日下跌1.0%，近一年下跌21.26%。科创创新药ETF国泰的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090800026116.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["589720","BK0216","688131"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665325646","title":"皓元医药涨6.31%，开源证券一周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2665325646","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665325646?lang=zh_cn&edition=full","pubTime":"2026-09-08 16:38","pubTimestamp":1788856735,"startTime":"0","endTime":"0","summary":"今日皓元医药涨6.31%，收盘报94.67元。2026年8月28日，开源证券研究员余汝意发布了对皓元医药的研报《公司信息更新报告：前端业务高景气驱动收入增长，后端订单加速蓄能》，该研报对皓元医药给出“买入”评级。研报中预计2026-2028年公司归母净利润为3.51/5.26/7.20亿元，EPS为1.65/2.47/3.38元，当前股价对应PE为56.9/37.9/27.7倍，维持“买入”评级。皓元医药个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090800026111.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688131","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665365679","title":"每周股票复盘：皓元医药（688131）皓元转债进入回售期","url":"https://stock-news.laohu8.com/highlight/detail?id=2665365679","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665365679?lang=zh_cn&edition=full","pubTime":"2026-09-06 01:48","pubTimestamp":1788630495,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘，皓元医药报收于88.83元，较上周的93.58元下跌5.08%。本周，皓元医药8月31日盘中最高价报93.93元。本周关注点公司公告汇总：因变更部分募集资金用途，“皓元转债”触发附加回售条款，回售期为2026年8月31日至9月4日。公司公告汇总上海皓元医药股份有限公司发布关于“皓元转债”可选择回售的第二次及第三次提示性公告。回售期间“皓元转债”停止转股，持有人可自主选择是否回售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090600000385.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688131"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664080513","title":"股市必读：皓元医药新发布《国联民生证券承销保荐有限公司关于上海皓元医药股份有限公司2026年半年度持续督导跟踪报告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664080513","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664080513?lang=zh_cn&edition=full","pubTime":"2026-09-04 01:03","pubTimestamp":1788454994,"startTime":"0","endTime":"0","summary":"公司公告汇总国联民生证券承销保荐有限公司关于上海皓元医药股份有限公司2026年半年度持续督导跟踪报告国联民生证券确认皓元医药2026年半年度整体运作规范，未发生重大违规事项；公司治理、内部控制、信息披露制度健全并有效执行；核心竞争力未发生不利变化；募集资金使用合规；控股股东及实际控制人未发生变化；主要财务数据显示营业收入和净利润稳步增长。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400001636.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0276","BK0216","601456","01456","BK1564","BK1147","161027","688131"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664863845","title":"股市必读：皓元医药新发布《上海皓元医药股份有限公司关于“皓元转债”可选择回售的第二次提示性公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664863845","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664863845?lang=zh_cn&edition=full","pubTime":"2026-09-02 01:14","pubTimestamp":1788282853,"startTime":"0","endTime":"0","summary":"截至2026年9月1日收盘，皓元医药报收于92.1元，下跌0.97%，换手率1.59%，成交量3.4万手，成交额3.11亿元。公司公告汇总上海皓元医药股份有限公司关于“皓元转债”可选择回售的第二次提示性公告上海皓元医药股份有限公司发布关于“皓元转债”可选择回售的第二次提示性公告。回售期间“皓元转债”停止转股，持有人可自主选择是否回售。截至公告披露日，债券收盘价高于回售价格，回售可能存在经济损失。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090200001797.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688131"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663045814","title":"每周股票复盘：皓元医药（688131）Q2收入增30.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663045814","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663045814?lang=zh_cn&edition=full","pubTime":"2026-08-30 09:00","pubTimestamp":1788051646,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，皓元医药报收于93.58元，较上周的97.39元下跌3.91%。来自公司公告汇总：“皓元转债”触发回售条款，回售期为2026年8月31日至9月4日，价格100.30元/张。股本股东变化截至2026年6月30日，皓元医药股东户数为1.59万户，较5月8日增加3979.0户，增幅33.43%。基本每股收益0.81元，同比增长12.50%。同日召开“皓元转债”2026年第二次债券持有人会议，出席会议债券持有人5名，代表未偿还债券635,550张，占总数7.7333%，议案获全票通过。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000004492.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688131"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662036067","title":"皓元医药（688131）2026年中报简析：营收净利润同比双双增长，应收账款上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2662036067","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662036067?lang=zh_cn&edition=full","pubTime":"2026-08-28 06:17","pubTimestamp":1787869064,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期皓元医药发布2026年中报。截至本报告期末，公司营业总收入16.48亿元，同比上升25.71%，归母净利润1.71亿元，同比上升12.81%。本报告期皓元医药应收账款上升，应收账款同比增幅达31.02%。截至2026年一季度末，公司后端小分子在手订单8.6亿元，已连续六个季度环比正增长；DC大分子在手订单已突破1亿元。目前，公司后端业务在手订单充足，签单趋势良好，为2026年全年业绩稳健增长提供了坚实保障。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800010929.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688131"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662374493","title":"股市必读：皓元医药新发布《上海皓元医药股份有限公司关于2026年半年度利润分配方案的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2662374493","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662374493?lang=zh_cn&edition=full","pubTime":"2026-08-27 04:18","pubTimestamp":1787775493,"startTime":"0","endTime":"0","summary":"交易信息汇总资金流向8月26日主力资金净流入552.77万元，占总成交额0.96%；游资资金净流入1814.99万元，占总成交额3.16%；散户资金净流出2367.75万元，占总成交额4.12%。公司公告汇总上海皓元医药股份有限公司关于2026年半年度利润分配方案的公告上海皓元医药股份有限公司于2026年8月25日召开董事会，审议通过2026年半年度利润分配方案。以截至2026年8月25日总股本213,234,092股计算，合计拟派发现金红利19,191,068.28元（含税），占2026年半年度归属于上市公司股东净利润的11.21%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700009668.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688131"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662746260","title":"图解皓元医药中报：第二季度单季净利润同比增长15.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662746260","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662746260?lang=zh_cn&edition=full","pubTime":"2026-08-27 01:46","pubTimestamp":1787766393,"startTime":"0","endTime":"0","summary":"证券之星消息，皓元医药2026年中报显示，上半年度公司主营收入16.48亿元，同比上升25.71%；归母净利润1.71亿元，同比上升12.81%；扣非净利润1.55亿元，同比上升10.21%；其中2026年第二季度，公司单季度主营收入9.19亿元，同比上升30.43%；单季度归母净利润1.03亿元，同比上升15.64%；单季度扣非净利润8862.44万元，同比上升8.54%；负债率50.01%，投资收益31.11万元，财务费用6996.79万元，毛利率50.76%。财报数据概要请见下图:本文数据来源于皓元医药2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700005308.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688131"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662219782","title":"8月25日皓元医药涨6.94%，科创创新药ETF国泰基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2662219782","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662219782?lang=zh_cn&edition=full","pubTime":"2026-08-25 16:36","pubTimestamp":1787646991,"startTime":"0","endTime":"0","summary":"证券之星消息，8月25日皓元医药涨6.94%，收盘报98.02元，换手率3.3%，成交量7.04万手，成交额6.72亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共27家，其中持有数量最多的公募基金为国泰基金的科创创新药ETF国泰。科创创新药ETF国泰目前规模为21.97亿元，最新净值0.9035，较上一交易日下跌5.32%，近一年下跌13.25%。科创创新药ETF国泰的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500033729.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688131","589720","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661222059","title":"皓元医药（688131）披露关于可转债募投项目暂缓实施及募集资金用途变更的议案获通过，8月24日股价下跌5.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661222059","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661222059?lang=zh_cn&edition=full","pubTime":"2026-08-24 17:37","pubTimestamp":1787564224,"startTime":"0","endTime":"0","summary":"截至2026年8月24日收盘，皓元医药报收于91.66元，较前一交易日下跌5.88%，最新总市值为195.45亿元。该股当日开盘97.51元，最高98.16元，最低90.9元，成交额达5.59亿元，换手率为2.81%。近日，上海皓元医药股份有限公司发布2026年第一次临时股东会决议公告。公司于2026年8月21日召开2026年第一次临时股东会，审议通过《关于向不特定对象发行可转换公司债券部分募投项目暂缓实施并变更部分募集资金用途的议案》。议案获通过，中小投资者已单独计票。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400024803.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688131","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661221230","title":"8月24日皓元医药跌5.88%，科创创新药ETF国泰基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2661221230","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661221230?lang=zh_cn&edition=full","pubTime":"2026-08-24 16:33","pubTimestamp":1787560385,"startTime":"0","endTime":"0","summary":"证券之星消息，8月24日皓元医药跌5.88%，收盘报91.66元，换手率2.81%，成交量5.99万手，成交额5.59亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共27家，其中持有数量最多的公募基金为国泰基金的科创创新药ETF国泰。科创创新药ETF国泰目前规模为21.97亿元，最新净值0.9543，较上一交易日下跌4.64%，近一年下跌7.36%。科创创新药ETF国泰的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400021823.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688131","BK0216","589720"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660466646","title":"皓元医药：ADC同一厂区一体化模式旨在将抗体原液、高活性载荷、生物偶联及制剂灌装等核心环节集中在同一物理空间内","url":"https://stock-news.laohu8.com/highlight/detail?id=2660466646","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660466646?lang=zh_cn&edition=full","pubTime":"2026-08-18 17:45","pubTimestamp":1787046312,"startTime":"0","endTime":"0","summary":"安徽和重庆同属皓元体系，共享统一的质量标准和技术转移流程。公司已构建起了“同一厂区商业化生产矩阵”——实现从抗体原液、高活性载荷、生物偶联到无菌制剂灌装的全链条闭环。随着重庆抗体制剂扩建项目2028年投产，公司ADC全链条自给能力将进一步增强。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800031571.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688131"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660456438","title":"皓元医药可转债2亿募资项目中途转向 为国联民生项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2660456438","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660456438?lang=zh_cn&edition=full","pubTime":"2026-08-18 10:34","pubTimestamp":1787020445,"startTime":"0","endTime":"0","summary":"中国经济网北京8月18日讯 中国经营网8月15日发表文章《皓元医药可转债项目生变 2亿募资中途转向》称，2024年12月才拿到约8.22亿元可转债募集资金，尚不足两年，皓元医药 核心募投项目便出现重大调整。核查意见显示，保荐机构对皓元医药向不特定对象发行可转换公司债券部分募投项目暂缓实施并变更部分募集资金用途的事项无异议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260818/32338053.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1564","601456","688131","SABA","01456","FCEF","BK0276","BK1147","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659759021","title":"每周股票复盘：皓元医药（688131）ADC基地获FDA审计通过","url":"https://stock-news.laohu8.com/highlight/detail?id=2659759021","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659759021?lang=zh_cn&edition=full","pubTime":"2026-08-16 01:42","pubTimestamp":1786815730,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘，皓元医药报收于100.08元，较上周的94.5元上涨5.9%。本周关注点来自公司公告汇总：全资子公司药源启东以零缺陷通过美国FDA现场检查。公司公告汇总上海皓元医药全资子公司药源生物科技（启东）有限公司于2026年6月22日至26日接受美国FDA药品批准前检查，检查范围为口服固体制剂。公司已收到FDA签发的现场检查报告，确认以零缺陷通过，未开具FDA483表格。此为公司制剂基地首次通过FDA检查，有助于拓展美国市场。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081600000270.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688131"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659514756","title":"皓元医药（688131）披露募集资金用途调整公告，8月14日股价上涨1.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659514756","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659514756?lang=zh_cn&edition=full","pubTime":"2026-08-14 22:10","pubTimestamp":1786716614,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘，皓元医药报收于100.08元，较前一交易日上涨1.12%，最新总市值为213.4亿元。该股当日开盘99.66元，最高101.39元，最低97.18元，成交额达6.24亿元，换手率为2.95%。近日，皓元医药发布关于调整部分募集资金投资项目及使用募集资金向控股子公司提供借款的公告。新项目总投资21,621.72万元，拟使用募集资金20,000.00万元，建设周期至2028年1月。项目实施主体为公司控股子公司重庆皓元，公司将以借款形式提供资金，年利率不低于3.83%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400039764.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688131","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659132243","title":"8月13日皓元医药涨5.18%，科创创新药ETF国泰基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2659132243","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659132243?lang=zh_cn&edition=full","pubTime":"2026-08-13 16:36","pubTimestamp":1786610178,"startTime":"0","endTime":"0","summary":"证券之星消息，8月13日皓元医药涨5.18%创60日新高，收盘报98.97元，换手率4.58%，成交量9.76万手，成交额9.74亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共27家，其中持有数量最多的公募基金为国泰基金的科创创新药ETF国泰。科创创新药ETF国泰目前规模为21.97亿元，最新净值0.9626，较上一交易日下跌0.65%，近一年下跌1.44%。科创创新药ETF国泰的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300026843.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688131","589720","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659187744","title":"CXO强者恒强！药明康德AH股齐升，皓元医药涨超8%！华宝基金医疗ETF（512170）涨超2%冲击五连阳","url":"https://stock-news.laohu8.com/highlight/detail?id=2659187744","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659187744?lang=zh_cn&edition=full","pubTime":"2026-08-13 11:25","pubTimestamp":1786591500,"startTime":"0","endTime":"0","summary":"8月13日，AH医疗板块迅速反弹。CXO强者恒强，药明康德AH股双双涨逾1%，康龙化成AH股齐升逾4%，A股皓元医药涨超7%。场内高CXO含量ETF同步走走强，CXO含量超50%的港股通医疗ETF华宝涨逾1%。全市场规模最大医疗ETF华宝CXO含量超30%，盘中涨超2%冲击五连阳，成交超4.5亿元。紧跟医疗反攻行情，关注两大“利器”：港股通医疗ETF华宝：最新CXO含量达51.88%，其中药明系权重占比超38%。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-13/doc-ininctaw3414344.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["512170","LU1969619763.USD","LU0052750758.USD","LU1997245094.SGD","LU2328871848.SGD","LU1719994722.HKD","CXO","LU1251922891.USD","BK1576","IE00B5MMRT66.SGD","LU1770034418.SGD","LU0456842615.SGD","BK1141","LU2242644610.SGD","IE00BPRC5H50.USD","LU0611395673.USD","603259","WX","LU2488822045.USD","02359","LU1979443071.USD","BK1583","LU2495084118.USD","LU2045819591.USD","159828","BK0216","LU0348766576.USD","LU1303224171.USD","LU1997244956.HKD","LU1997245177.USD","LU1934453819.USD","IE00B543WZ88.USD","LU1046422090.SGD","LU0348767384.USD","LU2125910500.SGD","LU1808992512.USD","LU0320764599.SGD","LU0700851271.USD","LU0708995583.HKD","688131"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658976075","title":"皓元医药(688131.SH)子公司药源启东通过美国FDA审计","url":"https://stock-news.laohu8.com/highlight/detail?id=2658976075","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658976075?lang=zh_cn&edition=full","pubTime":"2026-08-12 18:28","pubTimestamp":1786530504,"startTime":"0","endTime":"0","summary":"智通财经APP讯，皓元医药(688131.SH)发布公告，公司全资子公司药源生物科技(启东)有限公司(简称“药源启东”)于2026年6月22日至2026年6月26日接受了来自美国食品药品监督管理局(简称“FDA”)的药品批准前检查。近日，公司收到药源启东转发的美国FDA签发的现场检查报告，该报告表明药源启东以零缺陷通过本次现场检查。此次为公司制剂生产基地首次接受美国FDA检查并顺利通过，为公司持续拓展美国市场提供了坚实的保障。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479060.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK4588","688131","LABU","BK0216"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1788911621747,"stockEarnings":[{"period":"1week","weight":0.0279},{"period":"1month","weight":0.0018},{"period":"3month","weight":0.2702},{"period":"6month","weight":0.5711},{"period":"1year","weight":0.3584},{"period":"ytd","weight":0.3156}],"compareEarnings":[{"period":"1week","weight":-0.0099},{"period":"1month","weight":0.0001},{"period":"3month","weight":-0.0132},{"period":"6month","weight":-0.0457},{"period":"1year","weight":0.0297},{"period":"ytd","weight":-0.0071}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海皓元医药股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"15882人(较上一季度增加33.43%)","perCapita":"13426股","listingDate":"2021-06-08","address":"上海市浦东新区中国(上海)自由贸易试验区蔡伦路720弄2号501室","registeredCapital":"21323万元","survey":" 上海皓元医药股份有限公司的主营业务是药物发现领域的生命科学试剂的研发，原料药、中间体、起始物料及制剂的药物研发，工艺优化及商业化生产。公司的主要产品是生命科学试剂业务、原料药和中间体、制剂业务。","listedPrice":64.99},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"皓元医药(688131)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供皓元医药(688131)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"皓元医药,688131,皓元医药股票,皓元医药股票老虎,皓元医药股票老虎国际,皓元医药行情,皓元医药股票行情,皓元医药股价,皓元医药股市,皓元医药股票价格,皓元医药股票交易,皓元医药股票购买,皓元医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"皓元医药(688131)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供皓元医药(688131)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}